跳至主要内容
临床试验/NCT05574972
NCT05574972招募中不适用

A Prospective, Multi-center and Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Timing Carotid Stent for Carotid Artery Stenosis(Timing Trial)

Suzhou Zenith Vascular Scitech Co., Ltd.1 个研究点 分布在 1 个国家目标入组 178 人开始时间: 2022年10月18日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
178
试验地点
1
主要终点
Number of Participants Who Experienced Major Adverse Events (MAE) at 30 days

研究概览

简要总结

Evaluate the safety and efficacy of the Timing Carotid Stent for the treatment of carotid artery stenosis in patients.

详细描述

This is a prospective, randomized, concurrent controlled, multi-center study. Patients with carotid artery stenosis will be assigned to either the Timing Carotid Stent or Carotid Wallstent. Each treated patient will be followed and assessed for 12 months after randomization. The hypothesis to be tested is that the safety and effectiveness of the Timing Carotid Stent is not inferior to the Carotid Wallstent.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 18-85 years;
  • Patient is either symptomatic with carotid stenosis ≥50% OR asymptomatic with carotid stenosis ≥70% ;
  • Target lesion 3.5- 5.5 mm;
  • Signed informed consent.

排除标准

  • Target lesion is not caused by atherosclerotic disease;
  • Target lesion is located at the opening of the common carotid artery;
  • Patient has severe lesion calcification that may restrict the full deployment of the carotid
  • Patient has a total occlusion of the target carotid arteries
  • Patient has a large number of acute or subacute thrombi and arteriovenous malformations near the target lesion
  • Patient has a severe stenosis or occlusion in series with target lesions
  • Patient has known severe carotid stenosis contralateral to the target lesion
  • Patient need angioplasty in other parts (including intracranial and extracranial) at the same time or within 30 days after procedure
  • Patient has a symptomatic severe stenosis of other blood vessels (including intracranial and extracranial) except carotid artery
  • Patient is experiencing (or has experienced) an evolving, acute, or recent disabling stroke or intracranial hemorrhage
  • Patient has a massive stroke or myocardial infarction
  • Patient has a intracranial aneurysm
  • Patient has a coagulation dysfunction or abnormal bleeding, or contraindications to heparin and antiplatelet drugs
  • Patient has known sensitivity to contrast agent
  • Patient has a platelet < 90 × 109 / L, severe liver and kidney injury, and severe dysfunction of important organs such as heart, lung, liver and kidney
  • Patient has a uncontrollable severe hyperemia
  • Patient has a bradycardia
  • Patient has life expectancy of less than one year
  • Patient is currently enrolled in another investigational study protocol
  • Females who are pregnant or in lactation
  • Other conditions not suitable for inclusion judged by the researcher -

结局指标

主要结局

Number of Participants Who Experienced Major Adverse Events (MAE) at 30 days

时间窗: 30 days

MAE defined as any death, stroke, or myocardial infarction through 30 days post-index procedure

次要结局

  • mRS score change(1 year)
  • Number of Participants Who Achieved Stent Technical Success(Procedural)
  • Number of Participants Who Achieved Procedure Success(Procedural)
  • Ipsilateral ischemic stroke(1 year)
  • In-Stent Restenosis(1 year)
  • Target Lesion Revascularization(30 days)

研究者

发起方
Suzhou Zenith Vascular Scitech Co., Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验